Revive Therapeutics Ltd. ("
Revive") (TSX-V:RVV)
(OTCQB:RVVTF), a company focused on the research, development and
commercialization of novel cannabinoid solutions, and Ehave, Inc.
(“Ehave”) (OTCQB:EHVVF), a healthcare company dedicated to
empowering the mental health community with next-generation digital
solutions, are pleased to announce that they have entered into a
collaboration agreement to enable enhanced patient and clinical
research data management for Revive’s research initiatives
involving medical cannabis for the treatment of liver diseases.
The collaboration agreement will leverage
Ehave’s core expertise in health informatics through its Ehave
Connect platform. Revive will integrate the Ehave Connect
solution of diagnostic and treatment tools with its ongoing
research initiatives in liver disease to improve the lives of
patients. Ehave Connect will collect and integrate patient
data from clinical systems, licensed health surveys, and Ehave’s
own patient- and clinician-reported outcome applications,
empowering users with an end-to-end patient management solution,
allowing for better treatment decisions across teams and
disciplines while keeping patients informed and engaged throughout
their healthcare journey.
“We are very excited with our collaboration with
Ehave as it provides us with a foundation of employing next
generation patient and clinical research data management solutions
early on in the research and development phase of our liver disease
program,” said Craig Leon, Chief Executive Officer of Revive.
“Ehave’s Platform will support our research and clinical decisions
and it will allow us to make objective, data-driven decisions
throughout the course of our research and may provide unique
insights to expand our initiatives with cannabinoids for the
potential treatment of liver diseases such as non-alcoholic fatty
liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and
fibrosis.”
“Our collaboration with Revive is an important
step toward realizing Ehave’s broader goal of partnering with the
healthcare community, and in particular companies advancing novel
medical cannabis products, to facilitate clinical trials and
patient management with a single easy-to-use, end-to-end data
informatics platform,” stated Prateek Dwivedi, President and CEO of
Ehave. “Not only will this collaboration help to streamline
Revive’s research and clinical programs, but it also stands to
further establish Ehave’s position as a leader in the health
informatics space.”
About Ehave, Inc.
Ehave, Inc. (OTCQB: EHVVF) is empowering the
mental healthcare community with a next generation of data-rich
tools designed to improve patient management, diagnosis and
treatment. With Ehave Connect, Ehave's mental health informatics
platform, clinicians can make objective, data-driven decisions
while keeping patients informed and engaged throughout their mental
healthcare journey. Ehave Connect offers a powerful set of core
features that integrate with a growing selection of tools and
applications developed by Ehave and its leading partners, including
Multi-Health Systems ("MHS"), a leading publisher of psychological
assessments. Ehave is initially focused on improving the standard
of care in attention deficit hyperactivity disorder ("ADHD"),
through its collaboration with the Hospital for Sick Children
("SickKids"). Ehave Connect is also being utilized to advance the
validation and optimization of medical cannabis, through its
collaboration with leading medical cannabis licensed producers. For
more information, visit www.ehave.com.
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX
VENTURE:RVV)(OTCQB:RVVTF) is focused on the research, development
and commercialization of novel therapies and technologies for the
medical cannabis and cannabinoid-based pharmaceutical markets.
Additional information on Revive is available at
www.ReviveThera.com
Ehave, Inc. Forward-Looking Statement
Disclaimer
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are based
on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company's
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements: (i) the initiation,
timing, progress and results of the Company’s research,
manufacturing and other development efforts; (ii) the Company’s
ability to advance its products to successfully complete
development and commercialization; (iii) the manufacturing,
development, commercialization, and market acceptance of the
Company’s products; (iv) the lack of sufficient funding to finance
the product development and business operations; (v) competitive
companies and technologies within the Company’s industry and
introduction of competing products; (vi) the Company’s ability to
establish and maintain corporate collaborations; (vii) loss of key
management personnel; (viii) the scope of protection the Company is
able to establish and maintain for intellectual property rights
covering its products and its ability to operate its business
without infringing the intellectual property rights of others; (ix)
potential failure to comply with applicable health information
privacy and security laws and other state and federal privacy and
security laws; and (x) the difficulty of predicting actions of the
USA FDA and its regulations. All forward-looking statements
included in this press release are made only as of the date of this
press release. The Company assumes no obligation to update any
written or oral forward-looking statement unless required by law.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
contained under the heading "Risk Factors" in Ehave, Inc.’s
Registration Statement on Form F-1 filed with the Securities and
Exchange Commission (SEC) on September 24, 2015, as amended, which
is available on the SEC's website, http://www.sec.gov.
Revive Therapeutics Ltd. Cautionary Note Regarding
Forward-Looking Statements
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute "forward-looking
information" that involves known and unknown risks and
uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as "believes", "anticipates", "intends", "expects",
"estimates", "may", "could", "would", "will", or "plan", and
similar expressions. Specifically, forward-looking statements in
this news release include, without limitation, statements
regarding: the granting of a patent for Bucillamine for the
treatment of gout; the potential efficacy and commercial viability
of Bucillamine for treatment of gout and Bucillamine for the
treatment of Cystinuria; expansion of the Bucillamine clinical
testing program; the Company's drug research and development, and
commercialization plans; the Company’s research, development and
commercialization plans for plant-based therapies, including
cannabinoids; the timing of operations; and estimates of market
conditions. These statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results or
events, performance, or achievements of Revive to differ materially
from those anticipated or implied in such forward-looking
statements. Since forward-looking statements are based on
assumptions and address future events and conditions, by their very
nature they involve inherent risks and uncertainties. The Company
believes that the expectations reflected in these forward-looking
statements are reasonable, but there can be no assurance that
actual results will meet management's expectations. In formulating
the forward-looking statements contained herein, management has
assumed: that business and economic conditions affecting Revive
will continue substantially in the ordinary course and will be
favourable to Revive; that clinical testing results will justify
commercialization of the Company's drug candidates; that Revive
will be able to obtain all requisite regulatory approvals to
commercialize its drug candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its drug
repurposing candidates on favourable terms. Although these
assumptions were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance can be
given that such events will occur in the disclosed time frames or
at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; the Company's ability to
raise additional capital if and when necessary; intellectual
property disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
Contact:
For Ehave, Inc.Tiberend
Strategic Advisors, Inc.Joshua Drumm, Ph.D. (Investors)(212)
375-2664jdrumm@tiberend.com
Janine McCargo (Media)646-604-5150jmccargo@tiberend.com
For Revive Therapeutics Ltd.Craig LeonChief
Executive OfficerRevive Therapeutics Ltd.Tel: (416) 272-5525Email:
craig@revivethera.comWebsite: www.revivethera.com
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Apr 2023 to Apr 2024